医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chung Jin Biotech Acquires Patent for Bee Venom Cosmetics Brand MEDIBEE with its Outstanding Technology

2023年11月02日 PM10:00
このエントリーをはてなブックマークに追加


 

ANSAN, South Korea

Chung Jin Biotech Co., Ltd, a company specializing in bee venom, has obtained a patent for the bee venom cosmetics brand ‘MEDIBEE’ with its 20 years of top-tier technology.

‘MEDIBEE’ has successively developed and produced masks, serums, patches, and creams. All MEDIBEE brand cosmetics contain the optimal ratio of bee venom peptides, setting them apart from other products.

‘MEDIBEE Repair Intensive Cream’ helps hydrate, improve wrinkles, and strengthen the skin barrier with eco-friendly components like plant extracts and purified bee venom. The main ingredients of the intensive cream include purified bee venom, which received FDA DMF 27321 certification for the first time in Korea, shea butter, and ceramide.

This cream-type product boasts a hypoallergenic, soft texture, anti-aging, whitening, and wrinkle care benefits. The creamy texture applies smoothly and quickly absorbs deep into the skin to provide moisturizing over time and a refreshing finish without being sticky or rubbed off.

Chung Jin Biotech exports its products to numerous regions, such as the Americas, Europe, the Middle East, Asia, and Oceania, and has also acquired overseas certifications such as CPNP and HALAL (vary by product).

For more information about Chung Jin Biotech and MEDIBEE, visit http://www.biovenom.com/ and https://www.medibee.org/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102640304/en/

CONTACT

EDL ENTERPRISE for Chung Jin Biotech Co., Ltd

Sujin Lee

lsj@edl.co.kr

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders